A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function
A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Soeul, 대한민국
- Yonsei University Severance Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
A. Inclusion Criteria
[The subjects with impaired hepatic function]
- The subjects who are 19 to 64 years old
- The subjects with stable hepatic disease and impaired hepatic function as Child-Pugh A or B
- Body Weight ≥ 55kg
- If females, Negative for pregnancy test at the screening and pre dose of Day 1
- The subjects who agreed with performing contraception during the study
- The subjects who agreed with written informed consent
[The subjects with normal hepatic function]
- The subjects who are 19 to 64 years old
- The subjects who are matched impaired hepatic function by gender, age(± 5years) and body weight(± 10kg)
- If females, Negative for pregnancy test at the screening and pre dose of Day 1
- The subjects who agreed with performing contraception during the study
- The subjects who agreed with written informed consent
B. exclusion criteria
[The subjects with impaired hepatic function]
- The subjects with impaired hepatic function as Child-Pugh C
- The subjects had a portosystemic shunt surgery
- The subjects had a liver transplantation or unsuitable for the study by the investigator's judgement(for examples, hepatic encephalopathy grade 3 or 4, stroke, heart failure, cancer etc.) but The subject is eligible to participate if had not chemotherapy or radiofrequency ablation therapy within 6months)
- The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
- The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1
- Positive for anti-HIV Ab or venereal disease research laboratory etc.
[The subjects with normal hepatic function]
- The subjects with liver disease or abnormal Laboratory test(Asparate transaminase >1.25 fold of upper normal limit, Alanine transaminase>1.25 fold of upper normal limit, Total bilirubin >1.5 fold of upper normal limit)
- The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
- Estimated Glomerular filtration rate < 60 mL/min/1.73m2 by Modification of Diet in Renal Disease formula
- Positive for HBsAg, anti-Hepatitis C virus Ab, anti-HIV Ab or venereal disease research laboratory
- The subjects with high blood pressure or low blood pressure(systolic blood pressure >150mmHg or <100mmHg, diastolic blood pressure>90mmHg or <60mmHg)
- The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1 etc.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Child Pugh A
CKD-501 will be administered to patients who are included Child Pugh A
|
CKD-501 0.5mg, PO(per oral), once
다른 이름들:
|
|
실험적: Child Pugh B
CKD-501 will be administered to patients who are included Child Pugh B
|
CKD-501 0.5mg, PO(per oral), once
다른 이름들:
|
|
실험적: Subject who are matched Child Pugh A
CKD-501 will be administered to the Subjects who are matched Child Pugh A
|
CKD-501 0.5mg, PO(per oral), once
다른 이름들:
|
|
실험적: Subject who are matched Child Pugh B
CKD-501 will be administered to the subjects who are matched Child Pugh B
|
CKD-501 0.5mg, PO(per oral), once
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Area Under the Concentration(last) and Cmax of CKD-501
기간: 0 to 48 hours
|
Sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 |
0 to 48 hours
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Tmax, Area Under the Concentration(inf), T1/2 and Clearance/F of CKD-501 and its metabolite
기간: 0 to 48 hours
|
Sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 |
0 to 48 hours
|
|
Fraction Unbound of CKD-501 and its metabolite
기간: 1 and 8 hours
|
sampling timepoint(hours) : 1, 8 |
1 and 8 hours
|
|
Area Under the Concentration(last) and Cmax of the metabolite
기간: o to 48 hours
|
sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 |
o to 48 hours
|
|
Metabolic ratio(metabolite/CKD-501)
기간: 0 to 48 hours
|
sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 |
0 to 48 hours
|
기타 결과 측정
기타 결과 측정
결과 측정 |
기간 |
|---|---|
|
Vital signs
기간: up to 8 days
|
up to 8 days
|
|
Physical examination
기간: up to 8 days
|
up to 8 days
|
|
Laboratory tests
기간: up to 8 days
|
up to 8 days
|
|
Adverse events
기간: up to 8 days
|
up to 8 days
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .